Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Feb 2019 – Mar 2025Where it's discussed
-
X / Twitter154 posts
-
Facebook26 posts
-
News26 articles
-
Blogs6 articles
-
YouTube3 videos
AI synopsis
What people are saying
In the discussions, many participants referenced specific studies like the AVERT trial, highlighting that apixaban significantly reduces VTE incidence compared to placebo. Phrases like 'game changer' and 'must consider' express a sense of urgency and importance, suggesting that the findings could lead to notable changes in clinical practice. The tone is generally positive and enthusiastic, indicating a strong commitment to advancing patient care.
Most discussions reflect a supportive view toward the research findings, acknowledging the benefits of apixaban.
The conversations demonstrate a high level of curiosity about the implications of apixaban in VTE prevention for cancer patients.
While many participants share basic information, several delve into specific studies such as AVERT and its findings, showing some depth of engagement.
Contributors perceive the research as having a significant influence on treatment protocols for patients with cancer at risk for VTE.
Abstract in brief
- Patients with cancer face a higher risk of venous thromboembolism (VTE), increasing their health complications and costs; the Khorana score helps identify those at higher risk for this condition.
- A clinical trial tested the effectiveness and safety of apixaban, given at 25 mg twice daily, in cancer patients at intermediate-to-high risk for VTE who were starting chemotherapy.
- Results showed that apixaban significantly reduced the incidence of VTE compared to placebo, but it also led to a higher rate of major bleeding episodes.
Top posts
Most liked on X and BlueskyMany thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #APICAT Study https://t.co/PxhA8xSIln… via @YouTube @INNOVTE1 @isth @ICTHIC @ESC_Editions @CNCHcollege @Echoraljpangio @FrenchCardioOnc @gunnar_heine https://t.co/7DF39LC2fl
New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer and Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. Come and be a part of the conversation!
Apixaban to prevent venous thromboembolism in patients with cancer https://t.co/TNf5mPCP4r
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/5eRwZbZCLc
Patients with cancer who have an intermediate-high risk of developing a DVT/PE (identified using the Khorana score) can benefit from prophy dose apixiban, with about a 6% absolute reduction in thromboembolism, although increased rates of major bleeding https://t.co/jzdJlFNVlt
All mentions
Long-term Anticoagulation in Cancer-Associated Thrombosis
Recent Advances in Cardiology: Key Publications Overview
Clinical Trial Milestone 5
https://t.co/NDGi8u8Nx9
RT @isabellemahe1: Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #AP…
RT @isabellemahe1: Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #AP…
RT @isabellemahe1: Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #AP…
RT @isabellemahe1: Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #AP…
RT @isabellemahe1: Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #AP…
RT @isabellemahe1: Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #AP…
Many thanks for the opportunity to discuss the extended treatment in patients with #cancer and #thrombosis: #EVE and #APICAT Study https://t.co/PxhA8xSIln… via @YouTube @INNOVTE1 @isth @ICTHIC @ESC_Editions @CNCHcollege @Echoraljpangio @FrenchCardioOnc @gunnar_heine https://t.co/7DF39LC2fl
RT @gunnar_heine: Love CAT? Here comes All about EVE & Preview API-CAT with Prof. Robert McNane from @MayoClinic and @isabellemahe1 From @…
Love CAT? Here comes All about EVE & Preview API-CAT with Prof. Robert McNane from @MayoClinic and @isabellemahe1 From @isth 2023 Late Breakers https://t.co/mZ3vKGwruG via @YouTube Partners @dgfn_ev @oegnephro @com_SFNDT
RT @Pharma_nishi: 参考文献: ・Khoranaスコア https://t.co/dWMoj62HVL ・アピキサバン https://t.co/18Nqnmlugt ・リバーロキサバン https://t.co/qYA9kWSBjR
参考文献: ・Khoranaスコア https://t.co/dWMoj62HVL ・アピキサバン https://t.co/18Nqnmlugt ・リバーロキサバン https://t.co/qYA9kWSBjR
Catedra: Ingles Medico Topic: APIXABAN TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER Dr. @jack richrads Nombre: José Sarzosa Dale like y comenta
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
Khorana score for VTE risk in cancer patients:
昨日の抄読会、アピキサバン癌患者の血栓症一次予防。非常に面白かった!Khoranaスコアに限界を感じたし、組み入れ症例のリスクが血栓・出血ともに低かったなぁ。もっとリスキーな人々を見ることの方が多い。 the AVERT Investigators、NEJM https://t.co/aH7lPAp1vp
RT @LesterLeung: Apixaban for VTE prevention or treatment in patients with cancer https://t.co/k7iH8IqrFq https://t.co/aAz1Vof6Hl This come…
Apixaban for VTE prevention or treatment in patients with cancer https://t.co/k7iH8IqrFq https://t.co/aAz1Vof6Hl This comes up a lot for our middle-aged patients with #stroke and cancer with hypercoagulability
AVERT compared VTE in patients treated prophylactically with the DOAC apixaban or placebo. VTE occurred less often in the apixaban group than in the placebo group (HR, 0.41; 95% CI, 0.26–0.65; P < 0.001). https://t.co/i5r469NHHn https://t.co/QpTHMjaDNc
Apixaban to prevent venous thromboembolism in patients with cancer https://t.co/TNf5mPCP4r
@cilianjames @jdmcgee123 @steph_10g @mmc_im https://t.co/2rx4e4oWzd Apixaban (Eliquis) is superior to placebo in the outpatient setting for VTE prophylaxis in patients with high risk-VTE (Khorana ≥ 2)
RT @MDanmolsingh: Patients with cancer who have an intermediate-high risk of developing a DVT/PE (identified using the Khorana score) can b…
Patients with cancer who have an intermediate-high risk of developing a DVT/PE (identified using the Khorana score) can benefit from prophy dose apixiban, with about a 6% absolute reduction in thromboembolism, although increased rates of major bleeding https://t.co/jzdJlFNVlt
RT @Bhandoria: @drsadiejones @IndiraRosero @Aarti2008 @ARGO_COL @BGCS_org Here you go..@ASCO_pubs @NEJM @JAMA_current @IJGCfellows @IJGConl…
@drsadiejones @IndiraRosero @Aarti2008 @ARGO_COL @BGCS_org Here you go..@ASCO_pubs @NEJM @JAMA_current @IJGCfellows @IJGConline @ESGO_society @ENYGO_official https://t.co/jlkjp7NRjM https://t.co/s2kzAJZyls https://t.co/Ss61xUdMZp
RT @OncoCard_Ganken: for the treatment: Caravaggio study for the prevention: AVERT study #CAT #VTE #apixaban #CardioOnc Apixaban to Prev…
RT @OncoCard_Ganken: for the treatment: Caravaggio study for the prevention: AVERT study #CAT #VTE #apixaban #CardioOnc Apixaban to Prev…
RT @OncoCard_Ganken: for the treatment: Caravaggio study for the prevention: AVERT study #CAT #VTE #apixaban #CardioOnc Apixaban to Prev…
for the treatment: Caravaggio study for the prevention: AVERT study #CAT #VTE #apixaban #CardioOnc Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM https://t.co/ukIdmiOiQc 予防と治療とがある事を添えておきますね。 https://t.co/9hns3g4W6d
癌患者における #静脈血栓塞栓症予防 のための #アピキサバン Volume 380:711-719 Feburary 21, 2019 #NEJM #Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/5pcdoSxUdO #TopicsInPharmacotherapy #Pharmacotherapy #聖マリ薬剤部 #YearinReview2019
RT @tripdatabase: New2Trip: Gamechanger(?): Apixaban to prevent venous thromboembolism in patients w/ cancer https://t.co/mEklzRlmaT
New2Trip: Gamechanger(?): Apixaban to prevent venous thromboembolism in patients w/ cancer https://t.co/mEklzRlmaT
New2Trip: Gamechanger(?): Apixaban to prevent venous thromboembolism in patients w/ cancer https://t.co/mEklzRlmaT
New2Trip: Gamechanger(?): Apixaban to prevent venous thromboembolism in patients w/ cancer https://t.co/mEklzRlmaT
https://t.co/IzduKYcU5p
@grangeblanche Tu as cette etude vs placebo https://t.co/frvJJUmOSc
Want to learn more about apixaban use in the prevention of venous thromboembolism in pts w/ cancer? Article: https://t.co/aL6sth737t OR Listen to Blood&Cancer #podcast discussion on the latest recommendations on VTE prophylaxis in cancer pts Listen: https://t.co/qG3CISJXZD https://t.co/aLNvK10Rjr
RT @medpedshosp: AVERT trial https://t.co/7wogawL5B0
AVERT trial https://t.co/7wogawL5B0
RT @jawzaa_s: Study link: https://t.co/s02JqpG8SF
Study link: https://t.co/s02JqpG8SF
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/5eRwZbZCLc
RT @JTOonline: JTO Research Watch: "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer." #LCSM https://t.co/98wjWCNcL5
RT @JTOonline: JTO Research Watch: "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer." #LCSM https://t.co/98wjWCNcL5
RT @JTOonline: JTO Research Watch: "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer." #LCSM https://t.co/98wjWCNcL5
RT @JTOonline: JTO Research Watch: "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer." #LCSM https://t.co/98wjWCNcL5
RT @JTOonline: JTO Research Watch: "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer." #LCSM https://t.co/98wjWCNcL5
RT @JTOonline: JTO Research Watch: "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer." #LCSM https://t.co/98wjWCNcL5
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
RT @NEJM: New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients…
New @NEJMres360 Journal Club hosted by @UTHSC_Medicine Residency Program: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer and Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. Come and be a part of the conversation!
RT @oncoblogger: #Apixaban to Prevent Venous Thromboembolism in Patients with #Cancer | @NEJM https://t.co/qJ70cZOxgA
#Apixaban to Prevent Venous Thromboembolism in Patients with #Cancer | @NEJM https://t.co/qJ70cZOxgA
AVERT Trial Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/ZBnbvdpbgY https://t.co/5cka32KfNB
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
化学療法開始時にアピキサバン投与を行うと、プラセボに比べ静脈血栓塞栓が有意に減少。大出血イベントはプラセボよりアピキサバン群で多かった。トルーソーへの応用、適応拡大も期待したい。 Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM https://t.co/nTYUgGOXyA
Thromboprophylaxis with direct oral anticoagulants in ambulatory patients with cancer is effective and safe, studies suggest https://t.co/iXoStPVfnM
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
RT @RevEspCardiol: Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
Apixaban en la prevención de tromboembolismo venoso en pacientes con cancer via @NEJM https://t.co/Y9mgZ2EbgQ
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/lxRQYsomLC https://t.co/y3d4SYGeIo
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
#Apixaban to Prevent Venous #Thromboembolism in #Patients with #Cancer | #NEJM https://t.co/FubOLgaKNL
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM https://t.co/RmEz6mXvH0
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
Apixiban vs PLACEBO for VTE prevention in high risk cancer patients. Industry funded trash trial. Please tell me if I’m missing something https://t.co/rs3vY2bmPQ
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @RevEspCardiol: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer via @NEJM https://t.co/BHaWF5iAAc
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @RevEspCardiol: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer via @NEJM https://t.co/BHaWF5iAAc
#Apixaban to Prevent #Venous #Thromboembolism in Patients with #Cancer https://t.co/Rdy4UGPcLo
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM https://t.co/r44ciL5D3x
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
https://t.co/RhEfr10wOX
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @RevEspCardiol: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer via @NEJM https://t.co/BHaWF5iAAc
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer https://t.co/N9WU7tWyv2 #coagulation
RT @RevistaMFSamfyc: Apixabán para prevenir el tromboembolismo venoso en pacientes con cáncer https://t.co/Ams0gFNstZ PMID 30511879
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer via @NEJM https://t.co/BHaWF5iAAc
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer (AVERT) https://t.co/N9WU7tWyv2 Editorial:…
Apixabán para prevenir el tromboembolismo venoso en pacientes con cáncer https://t.co/Ams0gFNstZ PMID 30511879
@FZores Sinon tu as deux papiers tout neuf dans le New England sur apixaban et rivaro en prevention de la mtev/cancer https://t.co/A1XlGH83Hg https://t.co/wiFaIGHck9
がん患者がエリキュース2.5mgを1日2回服用することで、プラセボと比較して静脈血栓塞栓症のリスクを減らす https://t.co/Pvhm0jzGJo
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM https://t.co/8ACXu9pQYI
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM https://t.co/VVb9bx9ygT
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer (AVERT) https://t.co/N9WU7tWyv2 Editorial:…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @RevEspCardiol: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer via @NEJMGroup https://t.co/f0Loky3ETT https://t.co/3…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @RevEspCardiol: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer via @NEJMGroup https://t.co/f0Loky3ETT https://t.co/3…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: Original Article: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer (AVERT) https://t.co/N9WU7tWyv2 Editorial:…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…
RT @NEJM: New research into the use of apixaban to prevent venous thromboembolism in patients with cancer explained in Quick Take video: ht…